The Partnership for the Assessment of Risks from Chemicals (PARC) represents a joint effort among risk assessors, regulatory authorities, and the scientific community to advance the implementation of next-generation risk assessment (NGRA) in line with the objectives of the EU Chemicals Strategy for Sustainability. Addressing the challenges faced by the national and European regulators by integrating data generated through innovative methodologies is central to achieving this goal. Following an initial phase of the partnership, in which projects were defined based on a first prioritization of methodologies, a second prioritization round was conducted with input from the Governing Board representatives of all participating entities. This second process also considered the Key Areas of Regulatory Challenge introduced by the European Chemicals Agency in 2023, ensuring that the evolving research agenda within PARC is closely aligned with current and future regulatory needs. As a result, WP5 Hazard Assessment has updated its project portfolio to include four new projects that bridge identified regulatory gaps and strengthen the implementation phase of PARC. One project focuses on developmental and reproductive toxicity, another on developmental immunotoxicity, a third explores sexual dimorphism associated with hepatotoxicity, and a fourth transversal project, Regulatory Readiness of NAMs, aims to accelerate the regulatory uptake of promising methods developed under Work Package 5 (WP5). This article complements the previous PARC special issue by providing an overview of the updated WP5 project portfolio, illustrating the progression from prioritization to implementation, and highlighting how these new projects respond to evolving regulatory needs and contribute to the effective integration of new approach methodologies (NAMs) into chemical risk assessment.

Endocrine disruptors (EDs) are implicated in adverse developmental and reproductive outcomes, yet their identification remains a major challenge in chemical safety assessment. Current testing strategies rely heavily on animal models, which are constrained by ethical concerns, interspecies differences, and limited mechanistic resolution but justified by the complexity of the endocrine system and its physiology. Capturing the complex biology of intact organisms and incorporating toxicokinetic properties in alternative test methods is challenging. To address this, the European Partnership for the Assessment of Risks from Chemicals (PARC) is advancing the development and regulatory integration of new approach methodologies (NAMs). This project specifically contributes by developing and validating human-relevant NAMs to identify key aspects of endocrine disruption relevant to developmental and reproductive toxicity (DART). Key innovative activities include predictive modeling, refinement of zebrafish and amphibian embryo assays, and establishment of advanced in vitro systems for assessing toxicity in the oocyte, testis, placenta, and brain. By combining mechanistic insights with multi-modality and high throughput testing strategies, this work aims to improve the predictive power and regulatory utility of NAMs for ED identification within the One Health paradigm.

In response to increasing evidence of human and environmental health impacts of endocrine disrupting chemicals (EDCs), screening and testing programs for EDC assessment are being developed, requiring characterization of potential adverse health effects. The development of the lateral line (LL), a neurosensory system in fish, has been suggested as a potential toxicological target of EDCs. The LL contains neuromasts with hair cells (HCs) which convert mechanical stimuli into neural signals. An exploratory study was performed to assess whether neuromast development is affected by a selection of model EDCs with different modes of action. Zebrafish embryos were exposed to EDCs, targeting estrogen and thyroid pathways, immediately after fertilization. The number of HCs in four neuromasts was counted at 120 h post fertilization. Methimazole and resorcinol (thyroid hormone [TH] synthesis inhibitors) elicited the strongest response, characterized by a reduction in HC numbers, while fulvestrant (anti-estrogen) slightly increased HC numbers. Further investigation confirmed a reduction of HCs and neuromasts after exposure to methimazole during late embryonic development, when TH synthesis is active. Gene transcript level analysis revealed a decreased marker for HC activity and increased markers of support cells, essential for HC regeneration. Taken together, neuromast development appears to be affected by certain EDCs in zebrafish embryos, at concentrations similar to those causing other effects (e.g., impaired swim bladder inflation). However, variability in the responses complicates characterization using the FM1-43 method. Further research, including rescue experiments and more sensitive or functionally relevant methods, is needed to clarify the mechanisms underlying EDC-induced HC disruption.

Thyroid hormones (THs) are essential for growth, development, and metabolism across vertebrates. Thyroid hormone system disruption (THSD), as one of the mechanisms of endocrine disruption (ED), is widely recognised as a critical concern for both human and environmental health. Important challenges remain in the availability and regulatory application of methods for THSD assessment. Here we discuss recent methodological advances in the area of THSD, including validation efforts for in vitro assays and THSD-sensitive endpoints as additions to existing Organisation for Economic Co-operation and Development (OECD) Test Guidelines using fish early-life stages. We propose a modular adverse outcome pathway (AOP) network-based framework integrating mechanistic and effect-level information to support regulatory hazard assessment for both human and environmental health under a One Health paradigm. The framework summarises essential elements of the THSD AOP network relevant to human and environmental health and methods were mapped to these mechanism and effect components. In a case study on resorcinol, a chemical of regulatory interest relevant for both human and environmental health, we demonstrate how emerging methods, including in vitro and fish eleutheroembryo (developmental stage between hatching and the onset of independent feeding) assays as new approach methods (NAMs), complement traditional data to strengthen weight-of-evidence for ED classification. By mapping gaps and priorities, this work advances the integration of NAMs into chemical safety assessment, supporting a future update of OECD Guidance Document 150. These efforts align with European Union initiatives to gradually phase out animal testing for chemical hazard assessment and implement Next Generation Risk Assessment.

New Approach Methodologies (NAMs) are increasingly used across industrial sectors to assess chemicals for endocrine activity and support endocrine disruption assessment. The European Partnership for Alternative Approaches to Animal Testing (EPAA) conducted a strategic, cross-sector review of NAM-based frameworks within the EU regulatory context to capture lessons learned, identify scientific gaps, and explore opportunities for collaboration. A key challenge is that most current in vitro NAMs cannot, by design, demonstrate endocrine-mediated adversity in an intact organism. Because evidence of adversity is required to define an endocrine disruptor, this limits the ability of NAMs to replace animal-based endocrine disruptor tests unless clear links between endocrine activity and adverse outcomes are established. Refocusing adverse outcome pathways (AOPs) on improving the predictive capacity of endocrine activity assays, rather than directly demonstrating adversity, could enhance NAM development and application. Additional gaps include limited information on internal exposure, the role of potency, and adequate coverage of sensitive life stages—an issue relevant to both NAMs and in vivo studies. Building regulatory trust in existing and emerging in vitro and in silico methods is essential and will require agreement on acceptable levels of uncertainty and confidence that NAM-based predictions are equivalent to or better than current approaches. Developing robust validation frameworks, enabling cross-sector data sharing, and strengthening dialogue among regulators, academia, and industry are critical to accelerating the regulatory integration of NAMs in endocrine disruption assessment.

The ubiquitin-binding protein p62, encoded by Sequestosome 1 (SQSTM1), is an essential molecular adaptor for selective autophagy. Heterozygous mutations deleting or disrupting the ubiquitin-associated (UBA) domain of p62 have been reported as the major genetic cause for Paget’s disease of bone (PDB), the second most common skeletal disease, characterized by hyperactive osteoclasts and focal increases of bone turnover. In this study, we aimed to determine the impact of a similar sqstm1/p62 mutation on the skeleton of zebrafish. We successfully established a sqstm1tmΔUBA zebrafish line with premature truncation of the UBA domain and performed skeletal phenotyping of heterozygous and homozygous mutant zebrafish. Homozygous sqstm1tmΔUBA zebrafish suffered from early lethality after 6 mpf, possibly related to a dysregulated autophagy process. Nevertheless, we detected skeletal abnormalities that were generally more severe in older animals and in homozygous versus heterozygous sqstm1tmΔUBA zebrafish. MicroCT analysis and histologic staining showed alterations in the vertebral bodies and/or bone density in heterozygous sqstm1tmΔUBA zebrafish. We also detected signs of osteocytic osteolysis in carriers of a mutant sqstm1tmΔUBA allele, shown by a higher percentage of enlarged osteocyte lacunae at 12mpf (36

Metal pollution poses a persistent environmental challenge, impacting both ecosystems and human health. While efforts have been made to understand the mechanisms underlying the toxicological outcomes of metal pollution, there remains insufficient understanding of the key molecular and physiological events in co-exposure scenarios and across different life stages. We investigated the toxic effects of copper (0.80 μM Cu) and cadmium (0.25 μM Cd), both individually and in combination, on zebrafish (Danio rerio) embryos and adults. Key morphological and functional endpoints were assessed in embryos at 96 hours post-fertilisation (hpf) and in adults after seven days of exposure. Metal accumulation and molecular responses related to oxidative stress, apoptosis, metal transport, and DNA damage were studied at both life stages to gain insights into general and specific stress responses. The results show increased sensitivity of both embryos and adult animals to the co-exposure compared to single metal exposures. Embryos displayed higher vulnerability compared to adults. Oxidative stress emerged as a common mechanism of toxicity across both life stages, albeit with distinct defensive responses. Our results challenge the simplified assumption that metal accumulation alone can predict toxicity, highlighting the necessity of considering internal metal dynamics and physiological resilience. Investigations into other metal combinations and their effects on diverse species are warranted to fully elucidate the complexities of mixture toxicity in organisms.

A subgroup of endocrine-disrupting chemicals have the ability to disrupt metabolism. These metabolism-disrupting chemicals (MDCs) can end up in aquatic environments and lead to adverse outcomes in fish. Although molecular and physiological effects of MDCs have been studied in adult fish, few studies have investigated the consequences of metabolic disruption in fish during the earliest life stages. To investigate the processes affected by metabolic disruption, zebrafish embryos were exposed to peroxisome proliferator-activated receptor gamma (PPARγ) agonist rosiglitazone, the PPARγ antagonist T0070907, and the well-known environmentally relevant MDC bisphenol A. Decreased apolipoprotein Ea transcript levels indicated disrupted lipid transport, which was likely related to the observed dose-dependent increases in yolk size across all compounds. Increased yolk size and decreased swimming activity indicate decreased energy usage, which could lead to adverse outcomes because the availability of energy reserves is essential for embryo survival and growth. Exposure to T0070907 resulted in a darkened yolk. This was likely related to reduced transcript levels of genes involved in lipid transport and fatty acid oxidation, a combination of responses that was specific to exposure to this compound, possibly leading to lipid accumulation and cell death in the yolk. Paraoxonase 1 (Pon1) transcript levels were increased by rosiglitazone and T0070907, but this was not reflected in PON1 enzyme activities. The present study shows how exposure to MDCs can influence biochemical and molecular processes involved in early lipid metabolism and may lead to adverse outcomes in the earliest life stages of fish. Environ Toxicol Chem 2024;43:1880-1893. © 2024 The Author(s). Environmental Toxicology and Chemistry published by Wiley Periodicals LLC on behalf of SETAC.

Introduction: The Adverse Outcome Pathway (AOP) concept facilitates rapid hazard assessment for human health risks. AOPs are constantly evolving, their number is growing, and they are referenced in the AOP-Wiki database, which is supported by the OECD. Here, we present a study that aims at identifying well-defined biological areas, as well as gaps within the AOP-Wiki for future research needs. It does not intend to provide a systematic and comprehensive summary of the available literature on AOPs but summarizes and maps biological knowledge and diseases represented by the already developed AOPs (with OECD endorsed status or under validation).Methods: Knowledge from the AOP-Wiki database were extracted and prepared for analysis using a multi-step procedure. An automatic mapping of the existing information on AOPs (i.e., genes/proteins and diseases) was performed using bioinformatics tools (i.e., overrepresentation analysis using Gene Ontology and DisGeNET), allowing both the classification of AOPs and the development of AOP networks (AOPN).Results: AOPs related to diseases of the genitourinary system, neoplasms and developmental anomalies are the most frequently investigated on the AOP-Wiki. An evaluation of the three priority cases (i.e., immunotoxicity and non-genotoxic carcinogenesis, endocrine and metabolic disruption, and developmental and adult neurotoxicity) of the EU-funded PARC project (Partnership for the Risk Assessment of Chemicals) are presented. These were used to highlight under- and over-represented adverse outcomes and to identify and prioritize gaps for further research.Discussion: These results contribute to a more comprehensive understanding of the adverse effects associated with the molecular events in AOPs, and aid in refining risk assessment for stressors and mitigation strategies. Moreover, the FAIRness (i.e., data which meets principles of findability, accessibility, interoperability, and reusability (FAIR)) of the AOPs appears to be an important consideration for further development.

Thyroid hormones (THs) act early in ontogenesis, even prior to the differentiation of thyrocytes. Maternal transfer of THs is therefore known to play an essential role in early development. Current OECD test guidelines for the assessment of TH system disruption (THSD) do not address inter- or transgenerational effects. The integrated fish endocrine disruptor test (iFEDT), a test combining parental and developmental exposure of filial fish, may fill this gap. We tested the ability of the iFEDT to detect intergenerational effects in zebrafish (Danio rerio): Parental fish were exposed to propylthiouracil (PTU), an inhibitor of TH synthesis, or not exposed. The offspring was submitted to a crossed experimental design to obtain four exposure scenarios: (1) no exposure at all, (2) parental exposure only, (3) embryonic exposure only, and (4) combined parental and embryonic exposure. Swim bladder inflation, visual motor response (VMR) and gene expression of the progeny were analysed. Parental, but not embryonic PTU exposure reduced the size of the swim bladder of 5 d old embryos, indicating the existence of intergenerational effects. The VMR test produced opposite responses in 4.5 d old embryos exposed to PTU vs. embryos derived from exposed parents. Embryonic exposure, but not parental exposure increased gene expression of thyroperoxidase, the target of PTU, most likely due to a compensatory mechanism. The gene expression of pde-6h (phosphodiesterase) was reduced by embryonic, but not parental exposure, suggesting downregulation of phototransduction pathways. Hence, adverse effects on swim bladder inflation appear more sensitive to parental than embryonic exposure and the iFEDT represents an improvement in the testing strategy for THSD.

In past times, the analysis of endocrine disrupting properties of chemicals has mainly been focused on (anti-)estrogenic or (anti-)androgenic properties, as well as on aspects of steroidogenesis and the modulation of thyroid signaling. More recently, disruption of energy metabolism and related signaling pathways by exogenous substances, so-called metabolism-disrupting chemicals (MDCs) have come into focus. While general effects such as body and organ weight changes are routinely monitored in animal studies, there is a clear lack of mechanistic test systems to determine and characterize the metabolism-disrupting potential of chemicals. In order to contribute to filling this gap, one of the project within EU-funded Partnership for the Assessment of Risks of Chemicals (PARC) aims at developing novel in vitro methods for the detection of endocrine metabolic disruptors. Efforts will comprise projects related to specific signaling pathways, for example, involving mTOR or xenobiotic-sensing nuclear receptors, studies on hepatocytes, adipocytes and pancreatic beta cells covering metabolic and morphological endpoints, as well as metabolism-related zebrafish-based tests as an alternative to classic rodent bioassays. This paper provides an overview of the approaches and methods of these PARC projects and how this will contribute to the improvement of the toxicological toolbox to identify substances with endocrine disrupting properties and to decipher their mechanisms of action.

Thyroid hormone system disruption (THSD) is a growing concern in chemical hazard assessment due to its impact on human and environmental health and the scarce methods available for assessing the THSD potential of chemicals. In particular, the general lack of validated in silico and in vitro methods for assessing THS activity is of high concern. This manuscript provides an inventory of test methods relevant to THSD. Building on the Organisation for Economic Co-operation and Development (OECD) Guidance Document 150 and recent international developments, we highlight progress in in silico and in vitro methods, as well as in vivo assays. The provided inventory categorizes available methods according to the levels of the OECD Conceptual Framework, with an assessment of the validation status of each method. At Level 1, 12 in silico models that have been statistically validated and are directly related to THSD have been identified. At Level 2, 67 in vitro methods have been listed including those assessed in key initiatives such as the European Union Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL) validation study to identify potential thyroid disruptors. At Levels 3-5, THSD-sensitive endpoints are being included in existing fish-based OECD Test Guidelines to complement amphibian assays. In total, the inventory counts 108 entries comprising established methods (e.g., OECD Test Guidelines) as well as citable methods that are under further development and in some cases are ready for validation or in the initial stages of validation. This work aims to support the ongoing development of strategies for regulatory hazard assessment, such as integrated approaches to testing and assessment (IATAs), for endocrine disruptors, addressing critical gaps in the current testing landscape for THSD in both human and environmental health contexts.

Thyroid hormone system disruption (THSD) is a growing concern in chemical hazard assessment due to its impact on human and environmental health and the scarce methods available for assessing the THSD potential of chemicals. In particular, the general lack of validated in silico and in vitro methods for assessing THS activity is of high concern. This manuscript provides an inventory of test methods relevant to THSD. Building on the Organisation for Economic Co-operation and Development (OECD) Guidance Document 150 and recent international developments, we highlight progress in in silico and in vitro methods, as well as in vivo assays. The provided inventory categorizes available methods according to the levels of the OECD Conceptual Framework, with an assessment of the validation status of each method. At Level 1, 12 in silico models that have been statistically validated and are directly related to THSD have been identified. At Level 2, 67 in vitro methods have been listed including those assessed in key initiatives such as the European Union Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL) validation study to identify potential thyroid disruptors. At Levels 3-5, THSD-sensitive endpoints are being included in existing fish-based OECD Test Guidelines to complement amphibian assays. In total, the inventory counts 108 entries comprising established methods (e.g., OECD Test Guidelines) as well as citable methods that are under further development and in some cases are ready for validation or in the initial stages of validation. This work aims to support the ongoing development of strategies for regulatory hazard assessment, such as integrated approaches to testing and assessment (IATAs), for endocrine disruptors, addressing critical gaps in the current testing landscape for THSD in both human and environmental health contexts.

Environmental pollutants capable of interfering with the thyroid hormone (TH) system increasingly raise concern for both human and environmental health. Recently, resorcinol has received attention as a compound of concern due to its endocrine disrupting properties. It is a known inhibitor of thyroperoxidase (TPO), an enzyme required in TH synthesis, and therapeutic use of resorcinol exposure has led to hypothyroidism in humans. There is limited evidence concerning ecotoxicologically relevant effects of resorcinol in fish. A set of adverse outcome pathways (AOPs) has recently been developed linking thyroid hormone system disruption (THSD) to impaired swim bladder inflation and eye development in fish. In the present study, these AOPs were used to provide the background for testing potential THSD effects of resorcinol in zebrafish eleutheroembryos. We exposed zebrafish eleutheroembryos to resorcinol and assessed TH levels, swim bladder inflation and eye morphology. As a TPO inhibitor, resorcinol is expected to affect TH levels and eye morphology but not swim bladder inflation during embryonic development. Indeed, thyroxine (T4) levels were significantly decreased following resorcinol exposure. In contrast to our hypothesis, swim bladder inflation was impaired at 5 days post fertilization (dpf) and no effects on eye morphology were detected. Therefore, in vitro assays were performed to identify potential additional thyroid hormone system disruption-related mechanisms through which resorcinol may act. Two new mechanisms were identified: TH receptor (TR) antagonism and transthyretin (TTR) binding inhibition. Both of these mechanisms can plausibly be linked to impaired swim bladder inflation and could, therefore, explain the observed effect. Overall, our study contributes to the knowledge of the THSD potential of resorcinol both in vivo in the zebrafish model as well as in vitro.

There has been increasing interest in endocrine-disrupting chemicals (EDCs) among scientists and public authorities over the last 30 years, notably because of their wide use and the increasing evidence of detrimental effects on humans and the environment. However, test systems for the detection of potential EDCs as well as testing strategies still require optimization. Thus, the aim of the present project was the development of an integrated test protocol that merges the existing OECD test guidelines (TGs) 229 (fish short-term reproduction assay) and 234 (fish sexual development test) and implements thyroid-related endpoints for fish. The integrated fish endocrine disruptor test (iFEDT) represents a comprehensive approach for fish testing, which covers reproduction, early development, and sexual differentiation, and will thus allow the identification of multiple endocrine-disruptive effects in fish. Using zebrafish (Danio rerio) as a model organism, two exposure tests were performed with well-studied EDCs: 6-propyl-2-thiouracil (PTU), an inhibitor of thyroid hormone synthesis, and 17α-ethinylestradiol (EE2), an estrogen receptor agonist. In part A of this article, the effects of PTU and EE2 on established endpoints of the two existing TGs are reported, whereas part B focuses on the novel thyroid-related endpoints. Results of part A document that, as expected, both PTU and EE2 had strong effects on various endocrine-related endpoints in zebrafish and their offspring. Merging of TGs 229 and 234 proved feasible, and all established biomarkers and endpoints were responsive as expected, including reproductive and morphometric changes (PTU and EE2), vitellogenin levels, sex ratio, gonad maturation, and histopathology (only for EE2) of different life stages. A validation of the iFEDT with other well-known EDCs will allow verification of the sensitivity and usability and confirm its capacity to improve the existing testing strategy for EDCs in fish. Integr Environ Assess Manag 2024;20:817-829. © 2023 The Authors. Integrated Environmental Assessment and Management published by Wiley Periodicals LLC on behalf of Society of Environmental Toxicology & Chemistry (SETAC).

Given the vital role of thyroid hormones (THs) in vertebrate development, it is essential to identify chemicals that interfere with the TH system. Whereas, among nonmammalian laboratory animals, fish are the most frequently utilized test species in endocrine disruptor research, for example, in guidelines for the detection of effects on the sex hormone system, there is no test guideline (TG) using fish as models for thyroid-related effects; rather, amphibians are used. Therefore, the objective of the present project was to integrate thyroid-related endpoints for fish into a test protocol combining OECD TGs 229 (Fish Short-Term Reproduction Assay) and 234 (Fish Sexual Development Test). The resulting integrated Fish Endocrine Disruption Test (iFEDT) was designed as a comprehensive approach to covering sexual differentiation, early development, and reproduction and to identifying disruption not only of the sexual and/or reproductive system but also the TH system. Two 85-day exposure tests were performed using different well-studied endocrine disruptors: 6-propyl-2-thiouracil (PTU) and 17α-ethinylestradiol (EE2). Whereas the companion Part A of this study presents the findings on effects by PTU and EE2 on endpoints established in existing TGs, the present Part B discusses effects on novel thyroid-related endpoints such as TH levels, thyroid follicle histopathology, and eye development. 6-Propyl-2-thiouracil induced a massive proliferation of thyroid follicles in any life stage, and histopathological changes in the eyes proved to be highly sensitive for TH system disruption especially in younger life stages. For measurement of THs, further methodological development is required. 17-α-Ethinylestradiol demonstrated not only the well-known disruption of the hypothalamic-pituitary-gonadal axis, but also induced effects on thyroid follicles in adult zebrafish (Danio rerio) exposed to higher EE2 concentrations, suggesting crosstalk between endocrine axes. The novel iFEDT has thus proven capable of simultaneously capturing endocrine disruption of both the steroid and thyroid endocrine systems. Integr Environ Assess Manag 2024;20:830-845. © 2023 The Authors. Integrated Environmental Assessment and Management published by Wiley Periodicals LLC on behalf of Society of Environmental Toxicology & Chemistry (SETAC).